Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00065858 · ClinicalTrials.gov registry record · Phase 2
Effectiveness of BufferGel as a Vaginal Contraceptive
A Phase 2 study, sponsored by Premier Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 975
- Enrollment target
NCT00065858: Completed Phase 2 study, sponsored by Premier Research.
NCT00065858 is a Phase 2 study that has completed, run by Premier Research. The registered enrollment target is 975 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (633% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00065858, a Phase 2 study, has completed, sponsored by Premier Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 975 participants
- Enrollment target
Study Summary
BufferGel is a new contraceptive gel designed to be used with a diaphragm. In addition to preventing pregnancy, BufferGel may also prevent some types of sexually transmitted diseases (STDs). This study will compare BufferGel to Gynol II, a currently available contraceptive gel.
Interventions
- DRUG BufferGel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 975 participants |
| Start Date | 2001-09 |
| Est. Completion | 2005-04 |
| Phase | Phase 2 |
What the finished NCT00065858 record still lists
NCT00065858 is an interventional study that assigns participants to a tested intervention. The registered 975 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (633% higher).
The record links to 0 conditions, and to 1 intervention - of which BufferGel is the first listed.
NCT00065858 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00065858 about?
NCT00065858 is a clinical study titled "Effectiveness of BufferGel as a Vaginal Contraceptive". BufferGel is a new contraceptive gel designed to be used with a diaphragm. In addition to preventing pregnancy, BufferGel may also prevent some types of sexually transmitted diseases (STDs). This study will compare BufferGel to Gynol II, a currently available contraceptive gel.
What is the current status of trial NCT00065858?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 975 participants. The study started on 2001-09. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00065858?
The interventions under investigation include: BufferGel (DRUG).
Who is sponsoring clinical trial NCT00065858?
This trial is sponsored by Premier Research, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00065858's enrollment target sits among peer trials
975 28th of 2000 higher than 1,973 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05600777 · 975 participants · Phase 3
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
- NCT06541704 · 975 participants · Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
- NCT06820736 · 975 participants · NA
A Prospective, Randomized Comparison Of Drainage Techniques After One- Or Two-Level Open Posterior Lumbar Decompression Or Decompression And Fusion
- NCT07216482 · 975 participants · Phase 3
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia